Aggressive B-cell non-Hodgkin lymphoma
Clinical trials for Aggressive B-cell non-Hodgkin lymphoma explained in plain language.
Never miss a new study
Get alerted when new Aggressive B-cell non-Hodgkin lymphoma trials appear
Sign up with your email to follow new studies for Aggressive B-cell non-Hodgkin lymphoma, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Boosting transplants with donor immune cells to fight blood cancer relapse
Disease control Recruiting nowThis study tests whether giving donor white blood cells (lymphocytes) soon after a stem cell transplant can lower the chance of cancer returning in people with high-risk blood cancers like leukemia or lymphoma. Participants receive chemotherapy, a stem cell transplant, and then a…
Matched conditions: AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New antibody combo targets tough lymphoma in early trial
Disease control Recruiting nowThis study tests a new drug called EMB-07, which is a bispecific antibody that helps the immune system attack cancer cells. It is for people with aggressive B-cell non-Hodgkin lymphoma, either newly diagnosed or whose cancer has come back. The trial will check safety, side effect…
Matched conditions: AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA
Phase 1/2 • Sponsor: Shanghai EpimAb Biotherapeutics Co., Ltd. • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New 'Two-Pronged' CAR-T attack shows promise for tough blood cancers
Disease control Recruiting nowThis early-phase trial is testing a new treatment called OriV508 for people with multiple myeloma or non-Hodgkin lymphoma that has come back or stopped responding to other treatments. OriV508 is a type of immunotherapy that uses a virus to deliver instructions to the body to make…
Matched conditions: AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA
Early phase 1 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
New drug duo takes on tough lymphoma
Disease control Recruiting nowThis early-stage trial tests an experimental drug called REGN5837 combined with the approved drug odronextamab for people with aggressive B-cell lymphoma that has come back or not responded to prior treatments. The study first finds a safe dose, then checks how well the combo wor…
Matched conditions: AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA
Phase 1 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New CAR T-Cell therapy SynKIR-310 enters first human trial for Tough-to-Treat lymphoma
Disease control Recruiting nowThis early-phase study tests a new treatment called SynKIR-310 for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior therapies. The treatment uses a patient's own immune cells, modified to target and attack cancer cells. The main go…
Matched conditions: AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA
Phase 1 • Sponsor: Verismo Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC